Curanex Pharmaceuticals Inc Increase (Decrease) in Accrued Liabilities
Curanex Pharmaceuticals Inc (CURX) reported Increase (Decrease) in Accrued Liabilities of -$2.17 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$3.50K, a 242.99% decline year-over-year.
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $1.32K.
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $1.60K, a 70.35% decline year-over-year.
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $5.29K, a 47.79% increase year-over-year.
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for fiscal 2025 was $2.34K.
- Curanex Pharmaceuticals Inc increase (decrease) in accrued liabilities for fiscal 2024 was -$4.70K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.17K 10-Q · filed 2026-08-14 | -$575.00 derived: sum of 3 quarters · filed 2026-08-14 | $4.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.32K 10-Q · filed 2026-05-14 | $2.92K derived: sum of 2 quarters · filed 2026-05-14 | $8.22K derived: sum of 3 quarters · filed 2026-05-14 | $10.66K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.89K derived: sum of 2 quarters · filed 2026-03-30 | $9.34K derived: sum of 3 quarters · filed 2026-08-14 | $2.34K 10-K · filed 2026-03-30 |
| 2025-09-30 | $5.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $7.74K derived: sum of 2 quarters · filed 2026-08-14 | $741.00 10-Q · filed 2025-11-17 | $6.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.55K 10-Q · filed 2026-08-14 | $840.00 derived: sum of 3 quarters · filed 2026-08-14 | $4.42K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$7.00K 10-Q · filed 2026-05-14 | -$1.61K derived: sum of 2 quarters · filed 2026-05-14 | $1.98K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $5.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.97K derived: sum of 2 quarters · filed 2026-03-30 | -$4.70K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $3.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$10.09K 10-Q · filed 2025-11-17 | ||
| 2024-06-30 | -$13.68K 10-Q · filed 2025-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |